Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia
Status:
Unknown status
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This drug has been developed to treat Hyponatremia. The primary purpose of this study is to
verify the efficacy and safety of seven-day repeated oral administration of tolvaptan at 15,
30, and 60 mg or placebo in patients with Non-hypovolemic Non-acute Hyponatremia secondary to
Congestive Heart Failure (CHF), hepatic cirrhosis or Syndrome of Inappropriate Antidiuretic
Hormone (SIADH), despite receiving standard therapy. This study is being conducted in China.